Literature DB >> 14558674

Hyperprolactinemia in asymptomatic patients is related to high molecular weight posttranslational variants or glycosylated forms.

M Guitelman1, M E Colombani-Vidal, C C Zylbersztein, L Fiszlejder, M Zeller, O Levalle, H E Scaglia.   

Abstract

Circulating human Prolactin (PRL) exists in different variants related to posttranslational modifications, dimerization or association with other serum proteins. Compared to monomeric prolactin these variants usually have little or no biologic activity and include BigBig (BB PRL), Big (B PRL), and Glycosylated forms (G PRL). The aim of the present study was to assess levels of BB PRL, B PRL, little PRL (L PRL) and G PRL in hyperprolactinemic patients with no menstrual alterations or galactorrhea. L PRL, B PRL, and BB PRL were identified by gel filtration chromatography on Sephadex G-100; G PRL and NG PRL were identified by chromatography on Concanavalin A Sepharose. PRL was measured by IRMA DPC. Eleven women, aged 22-50 yrs, were studied for: breast dysplasia (1), controlled hypothyroidism (3), dysmenorrhea (3), microadenoma follow-up (2), and gynecological control (2). Pituitary MRI was normal in all but one patient, who had a microadenoma discovered by Magnetic Resonance Imaging. Six patients had normal L PRL levels, and their hyper PRL was due to excess BPRL or BB PRL. Five patients had increased L PRL levels, but excess G PRL. Patients harboring molecular PRL variants do not present the symptoms typical of the hyperprolactinemic syndrome. Furthermore in patients with clinically controlled prolactinomas the presence of PRL variants should be ruled out to avoid an unnecessary increase of dopamine agonist dosage.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 14558674     DOI: 10.1023/a:1025381917677

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  27 in total

1.  Prolactin decrease and shift to a normal-like isoform profile during treatment with quinagolide in a patient affected by an invasive prolactinoma.

Authors:  R Guido; S Valenti; L Foppiani; D De Martini; M Cossu; M Giusti
Journal:  J Endocrinol Invest       Date:  1997-05       Impact factor: 4.256

2.  Asymptomatic 'big' hyperprolactinemia in two men with pituitary adenomas.

Authors:  N A Tritos; A T Guay; W B Malarkey
Journal:  Eur J Endocrinol       Date:  1998-01       Impact factor: 6.664

3.  Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method.

Authors:  H Leslie; C H Courtney; P M Bell; D R Hadden; D R McCance; P K Ellis; B Sheridan; A B Atkinson
Journal:  J Clin Endocrinol Metab       Date:  2001-06       Impact factor: 5.958

Review 4.  Prolactin and growth hormone: molecular heterogeneity and measurement in serum.

Authors:  C R Smith; M R Norman
Journal:  Ann Clin Biochem       Date:  1990-11       Impact factor: 2.057

5.  Macroprolactinemia revisited: a study on 106 patients.

Authors:  Sophie Vallette-Kasic; Isabelle Morange-Ramos; Adel Selim; Ginette Gunz; Sophie Morange; Alain Enjalbert; Pierre-Marie Martin; Philippe Jaquet; Thierry Brue
Journal:  J Clin Endocrinol Metab       Date:  2002-02       Impact factor: 5.958

6.  Screening for macroprolactinaemia and pituitary imaging studies.

Authors:  Omar M Hauache; Antonio J Rocha; Antonio C M Maia; Rui M B Maciel; José Gilberto H Vieira
Journal:  Clin Endocrinol (Oxf)       Date:  2002-09       Impact factor: 3.478

7.  Autoantibody to human prolactin in patients with idiopathic hyperprolactinemia.

Authors:  N Hattori; T Ishihara; K Ikekubo; K Moridera; M Hino; H Kurahachi
Journal:  J Clin Endocrinol Metab       Date:  1992-11       Impact factor: 5.958

8.  Frequency of hyperprolactinaemia due to large molecular weight prolactin (150-170 kD PRL).

Authors:  T Bjøro; L Mørkrid; R Wergeland; A Turter; A Kvistborg; T Sand; P Torjesen
Journal:  Scand J Clin Lab Invest       Date:  1995-04       Impact factor: 1.713

9.  A new sensitive and specific bioassay for lactogenic hormones: measurement of prolactin and growth hormone in human serum.

Authors:  T Tanaka; R P Shiu; P W Gout; C T Beer; R L Noble; H G Friesen
Journal:  J Clin Endocrinol Metab       Date:  1980-11       Impact factor: 5.958

10.  Some forms of big big prolactin behave as a complex of monomeric prolactin with an immunoglobulin G in patients with macroprolactinemia or prolactinoma.

Authors:  B Cavaco; V Leite; M A Santos; E Arranhado; L G Sobrinho
Journal:  J Clin Endocrinol Metab       Date:  1995-08       Impact factor: 5.958

View more
  1 in total

1.  Prolactinoma and systemic lupus erythematosus: do serum prolactin levels matter?

Authors:  Margaret Li; Harold D Keiser; Elena Peeva
Journal:  Clin Rheumatol       Date:  2006-01-11       Impact factor: 2.980

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.